ArriVent BioPharma, Inc. (AVBP)

Market Cap	577.10M
Revenue (ttm)	n/a
Net Income (ttm)	-69.33M
Shares Out	33.49M
EPS (ttm)	-32.38
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,196
Open	16.99
Previous Close	16.80
Day's Range	16.76 - 17.51
52-Week Range	14.35 - 25.95
Beta	n/a
Analysts	Strong Buy
Price Target	29.25 (+69.76%)
Earnings Date	May 14, 2024

About AVBP

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal grow...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 26, 2024
• Employees: 40
• Stock Exchange: NASDAQ
• Ticker Symbol: AVBP

Analyst Forecast

According to 4 analysts, the average rating for AVBP stock is "Strong Buy." The 12-month stock price forecast is $29.25, which is an increase of 69.76% from the latest price.

Price Target

$29.25

(69.76% upside)

Analyst Consensus: Strong Buy